Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome.

Blood

Leukaemia Research Fund Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Science, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.

Published: June 2002

The 5q- syndrome is the most distinct of the myelodysplastic syndromes, and the molecular basis for this disorder remains unknown. We describe the narrowing of the common deleted region (CDR) of the 5q- syndrome to the approximately 1.5-megabases interval at 5q32 flanked by D5S413 and the GLRA1 gene. The Ensembl gene prediction program has been used for the complete genomic annotation of the CDR. The CDR is gene rich and contains 24 known genes and 16 novel (predicted) genes. Of 40 genes in the CDR, 33 are expressed in CD34(+) cells and, therefore, represent candidate genes since they are expressed within the hematopoietic stem/progenitor cell compartment. A number of the genes assigned to the CDR represent good candidates for the 5q- syndrome, including MEGF1, G3BP, and several of the novel gene predictions. These data now afford a comprehensive mutational/expression analysis of all candidate genes assigned to the CDR.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.v99.12.4638DOI Listing

Publication Analysis

Top Keywords

5q- syndrome
16
genomic annotation
8
deleted region
8
candidate genes
8
genes assigned
8
assigned cdr
8
cdr
6
genes
6
narrowing genomic
4
annotation commonly
4

Similar Publications

Chromosomes 5 and 7 are large chromosomes that contain close to 1,000 genes each. Deletions of the long arms or loss of the entire chromosome (monosomy) are common defects in myeloid disorders, particularly MDS and AML. Loss of material from either chromosome 5 or 7 results in haploinsufficiency of multiple genes, with some implicated in leukemogenesis.

View Article and Find Full Text PDF

Genome sequencing in the management of myelodysplastic syndromes and related disorders.

Haematologica

October 2024

Department of Molecular Medicine, University of Pavia, and Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia.

Article Synopsis
  • * Significant research has reshaped the understanding of MDS, uncovering key mutations in important genes and helping categorize the disease into distinct types based on these genetic changes.
  • * Advances in genomic profiling and the Molecular International Prognostic Scoring System (IPSS-M) are enhancing diagnosis and treatment personalization, emphasizing the need for collaborative efforts in healthcare and research.
View Article and Find Full Text PDF

The 5q deletion syndrome is a relatively rare condition caused by the monoallelic interstitial deletion of the long arm of chromosome 5. Patients described in literature usually present variable dysmorphic features, behavioral disturbance, and intellectual disability (ID); moreover, the involvement of the gene (5q22.2) in the deletion predisposes them to tumoral syndromes (Familial Adenomatous Polyposis and Gardner syndrome).

View Article and Find Full Text PDF

Approval of new agents to treat higher risk (HR) myelodysplastic syndrome (MDS) has stalled since the approval of DNA methyltransferase inhibitors (DNMTi). In addition, the options for patients with lower risk (LR) MDS who have high transfusion needs and do not harbor ring sideroblasts or 5q- syndrome are limited. Here, we review the current treatment landscape in MDS and identify areas of unmet need, such as treatment after failure of erythropoiesis-stimulating agents or DNMTis, TP53-mutated disease, and MDS with potentially targetable mutations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!